Elevated expression of IMPDH2 is associated with progression of kidney and bladder cancer

详细信息    查看全文

• 作者：Jun Zou (1) (2) (3)
  Zhaodong Han (2)
  Liang Zhou (2)
  Chao Cai (1)
  Hongwei Luo (1)
  Yaqiang Huang (1)
  Yuxiang Liang (2)
  Huichan He (2)
  Funeng Jiang (2)
  Cong Wang (4)
  Weide Zhong (1) (2) (5) (6)
  
• 关键词：Inosine 5-monophosphate dehydrogenase type II ; Kidney cancer ; Bladder cancer ; Testis cancer
• 刊名：Medical Oncology
• 出版年：2015
• 出版时间：January 2015
• 年：2015
• 卷：32
• 期：1
• 全文大小：5,513 KB
• 参考文献：1. Bairagya HR, Mukhopadhyay BP, Sekar K. An insight to the dynamics of conserved water molecular triad in IMPDH II (human): recognition of cofactor and substrate to catalytic Arg 322. J Biomol Struct Dyn. 2009;27(2):149-8. CrossRef
  2. Chen L, Petrelli R, Gao G, et al. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure. Bioorg Med Chem. 2010;18(16):5950-4. CrossRef
  3. Bowne SJ, Sullivan LS, Mortimer SE, et al. Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis. Invest Ophthalmol Vis Sci. 2006;47(1):34-2. CrossRef
  4. Floryk D, Tollaksen SL, Giometti CS, Huberman E. Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5-monophosphate dehydrogenase. Cancer Res. 2004;64(24):9049-6. CrossRef
  5. Thomas EC, Gunter JH, Webster JA, et al. Different characteristics and nucleotide binding properties of inosine monophosphate dehydrogenase (IMPDH) isoforms. PLoS One. 2012;7(12):e51096. CrossRef
  6. Han ZD, Zhang YQ, He HC, et al. Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis. Med Oncol. 2012;29(4):2877-8. CrossRef
  7. Zhou L, Xia D, Zhu J, et al. Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer. Clin Transl Oncol. 2014;16(10):906-3.
  8. Vethe NT, Bremer S, Bergan S. IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine. Scand J Clin Lab Invest. 2008;68(4):277-5. CrossRef
  9. He Y, Mou Z, Li W, et al. Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer using immunoproteomics analysis. Int J Colorectal Dis. 2009;24(11):1271-. CrossRef
  10. Fellenberg J, Bernd L, Delling G, Witte D, Zahlten-Hinguranage A. Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Mod Pathol. 2007;20(10):1085-4. CrossRef
  11. Li M, Su BS, Chang LH, et al. Oxymatrine induces apoptosis in human cervical cancer cells through guanine nucleotide depletion. Anticancer Drugs. 2014;25(2):161-3. CrossRef
  12. He HC, Ling XH, Zhu JG, et al. Down-regulation of the ErbB3 binding protein 1 in human bladder cancer promotes tumor progression and cell proliferation. Mol Biol Rep. 2013;40(5):3799-05. CrossRef
  13. Zhang Z, Zhang G, Kong C. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Urol Oncol. 2013;31(7):1222-0. CrossRef
  14. Soskine M, Tawfik DS. Mutational effects and the evolution of new protein functions. Nat Rev Genet. 2010;11(8):572-2. CrossRef
  15. Anantharaman V, Aravind L, Koonin EV. Emergence of diverse biochemical activities in evolutionarily conserved structural scaffolds of proteins. Curr Opin Chem Biol. 2003;7(1):12-0. CrossRef
  16. Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev. 2009;109(7):2903-8. CrossRef
  17. Morriso
• 作者单位：Jun Zou (1) (2) (3)
  Zhaodong Han (2)
  Liang Zhou (2)
  Chao Cai (1)
  Hongwei Luo (1)
  Yaqiang Huang (1)
  Yuxiang Liang (2)
  Huichan He (2)
  Funeng Jiang (2)
  Cong Wang (4)
  Weide Zhong (1) (2) (5) (6)
  
  1. Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou, 510515, China
  2. Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, 510180, China
  3. The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China
  4. School of Pharmacy, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China
  5. Urology Key Laboratory of Guangdong Province, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, 510230, China
  6. Department of Urology, Huadu District People’s Hospital, Southern Medical University, Guangzhou, 510800, China
  
• ISSN：1559-131X

文摘

Novel molecular markers for cancer progression are valuable for the diagnosis and evaluation of treatment efficacies of the diseases. Expression of inosine 5-monophosphate dehydrogenase type II (IMPDH2), a rate-limiting enzyme in the de novo guanine nucleotide biosynthesis, is up-regulated in various neoplasms, including prostate cancer and patient serum. However, whether IMPDH2 can serve as a biomarker for other urologic cancers is unknown. Paired patient tissue macroarrays were analyzed by immunohistochemistry, the IMPDH2 protein expression in these tissues was quantitated and expressed as immunoreactivity scores. Compared with non-cancerous tissues, IMPDH2 protein expression levels were significantly upregulated in kidney and bladder cancer, but no difference in testis cancer. In addition, expression of IMPDH2 was not associated with the disease clinical stages and pathological features. The findings suggest that overexpressed IMPDH2 can be used as a biomarker for kidney and bladder cancer diagnosis and is a potential therapeutic target for the diseases.